Report for: Intravenous immunoglobulin for Guillain-Barré syndrome

Title	Intravenous immunoglobulin for Guillain-Barré syndrome
Published in	Cochrane database of systematic reviews, September 2014
DOI	10.1002/14651858.cd002063.pub6
Pubmed ID	25238327
Authors	Richard AC Hughes, Anthony V Swan, Pieter A van Doorn
Abstract	Guillain-Barré syndrome (GBS) is an acute, paralysing, inflammatory peripheral nerve disease. Intravenous immunoglobulin (IVIg) is beneficial in other autoimmune diseases. This is an update of a review first published in 2001 and previously updated in 2003, 2005, 2007, 2010 and 2012. Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ineffective.

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
Brazil	1	20%
Australia	1	20%
United Kingdom	1	20%
Unknown	2	40%

Demographic breakdown

Type	Count	As %
Members of the public	5	100%

Mendeley readers

The data shown below were compiled from readership statistics for 555 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
United States	5	<1%
Netherlands	1	<1%
Norway	1	<1%
Fiji	1	<1%
Canada	1	<1%
Spain	1	<1%
Peru	1	<1%
Unknown	544	98%

Demographic breakdown

Readers by professional status	Count	As %
Student > Bachelor	80	14%
Student > Master	74	13%
Researcher	67	12%
Other	59	11%
Student > Postgraduate	55	10%
Other	113	20%
Unknown	107	19%

Readers by discipline	Count	As %
Medicine and Dentistry	218	39%
Nursing and Health Professions	39	7%
Neuroscience	36	6%
Pharmacology, Toxicology and Pharmaceutical Science	25	5%
Agricultural and Biological Sciences	21	4%
Other	84	15%
Unknown	132	24%

Attention Score in Context

This research output has an Altmetric Attention Score of 372. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2023.

All research outputs

#70,145

of 22,953,506 outputs

Outputs from Cochrane database of systematic reviews

#122

of 12,333 outputs

Outputs of similar age

#623

of 250,830 outputs

Outputs of similar age from Cochrane database of systematic reviews

of 220 outputs

Altmetric has tracked 22,953,506 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 12,333 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.6. This one has done particularly well, scoring higher than 99% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,830 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.

We're also able to compare this research output to 220 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.

Cochrane Database of Systematic Reviews

Intravenous immunoglobulin for Guillain-Barré syndrome

About this Attention Score

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context